{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T01:42:35Z","timestamp":1790646155989,"version":"4.1.0"},"reference-count":176,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2021,6,5]],"date-time":"2021-06-05T00:00:00Z","timestamp":1622851200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Spanish Health Institute Carlos III","award":["FIS PI17\/01930"],"award-info":[{"award-number":["FIS PI17\/01930"]}]},{"name":"Fondos FEDER (EU) and Junta Castilla-Le\u00f3n","award":["COV20EDU\/00187"],"award-info":[{"award-number":["COV20EDU\/00187"]}]},{"name":"Fundaci\u00f3n Sol\u00f3rzano","award":["FS\/38-2017"],"award-info":[{"award-number":["FS\/38-2017"]}]},{"name":"PRB3-ISCIII","award":["PT17\/0019\/0023"],"award-info":[{"award-number":["PT17\/0019\/0023"]}]},{"name":"JCYL PhD Program and scholarship","award":["JCYL-EDU\/601\/2020"],"award-info":[{"award-number":["JCYL-EDU\/601\/2020"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Immunogenic cell death (ICD) elicited by cancer therapy reshapes the tumor immune microenvironment. A long-term adaptative immune response can be initiated by modulating cell death by therapeutic approaches. Here, the major hallmarks of ICD, endoplasmic reticulum (ER) stress, and damage-associated molecular patterns (DAMPs) are correlated with ICD inducers used in clinical practice to enhance antitumoral activity by suppressing tumor immune evasion. Approaches to monitoring the ICD triggered by antitumoral therapeutics in the tumor microenvironment (TME) and novel perspective in this immune system strategy are also reviewed to give an overview of the relevance of ICD in cancer treatment.<\/jats:p>","DOI":"10.3390\/cancers13112821","type":"journal-article","created":{"date-parts":[[2021,6,6]],"date-time":"2021-06-06T23:59:55Z","timestamp":1623023995000},"page":"2821","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":63,"title":["Restoring the Immunity in the Tumor Microenvironment: Insights into Immunogenic Cell Death in Onco-Therapies"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5585-9918","authenticated-orcid":false,"given":"\u00c1ngela-Patricia","family":"Hern\u00e1ndez","sequence":"first","affiliation":[{"name":"Department of Medicine and General Cytometry Service-Nucleus, CIBERONC CB16\/12\/00400, Cancer Research Centre (IBMCC\/CSIC\/USAL\/IBSAL), 37007 Salamanca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9435-2952","authenticated-orcid":false,"given":"Pablo","family":"Juanes-Velasco","sequence":"additional","affiliation":[{"name":"Department of Medicine and General Cytometry Service-Nucleus, CIBERONC CB16\/12\/00400, Cancer Research Centre (IBMCC\/CSIC\/USAL\/IBSAL), 37007 Salamanca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Landeira-Vi\u00f1uela","sequence":"additional","affiliation":[{"name":"Department of Medicine and General Cytometry Service-Nucleus, CIBERONC CB16\/12\/00400, Cancer Research Centre (IBMCC\/CSIC\/USAL\/IBSAL), 37007 Salamanca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Halin","family":"Bareke","sequence":"additional","affiliation":[{"name":"Department of Medicine and General Cytometry Service-Nucleus, CIBERONC CB16\/12\/00400, Cancer Research Centre (IBMCC\/CSIC\/USAL\/IBSAL), 37007 Salamanca, Spain"},{"name":"Department of Pharmaceutical Biotechnology, Faculty of Pharmacy, Institute of Health Sciences, Marmara University, 34722 Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique","family":"Montalvillo","sequence":"additional","affiliation":[{"name":"Department of Medicine and General Cytometry Service-Nucleus, CIBERONC CB16\/12\/00400, Cancer Research Centre (IBMCC\/CSIC\/USAL\/IBSAL), 37007 Salamanca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8046-4301","authenticated-orcid":false,"given":"Rafael","family":"G\u00f3ngora","sequence":"additional","affiliation":[{"name":"Department of Medicine and General Cytometry Service-Nucleus, CIBERONC CB16\/12\/00400, Cancer Research Centre (IBMCC\/CSIC\/USAL\/IBSAL), 37007 Salamanca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7305-3766","authenticated-orcid":false,"given":"Manuel","family":"Fuentes","sequence":"additional","affiliation":[{"name":"Department of Medicine and General Cytometry Service-Nucleus, CIBERONC CB16\/12\/00400, Cancer Research Centre (IBMCC\/CSIC\/USAL\/IBSAL), 37007 Salamanca, Spain"},{"name":"Proteomics Unit, Cancer Research Centre (IBMCC\/CSIC\/USAL\/IBSAL), 37007 Salamanca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,6,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0092-8674(00)81683-9","article-title":"The hallmarks of cancer","volume":"100","author":"Hanahan","year":"2000","journal-title":"Cell"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of Cancer: The Next Generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.drup.2012.01.006","article-title":"The tumor microenvironment is a dominant force in multidrug resistance","volume":"15","author":"Correia","year":"2012","journal-title":"Drug Resist. Updates"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Kersten, K., Salvagno, C., and de Visser, K.E. (2015). Exploiting the immunomodulatory properties of chemotherapeutic drugs to improve the success of cancer immunotherapy. Front. Immunol., 6.","DOI":"10.3389\/fimmu.2015.00516"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1126\/science.1203486","article-title":"Cancer Immunoediting: Integrating Immunity\u2019s Roles in Cancer Suppression and Promotion","volume":"331","author":"Schreiber","year":"2011","journal-title":"Science"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1084\/jem.20112738","article-title":"Cancer immunoediting by the innate immune system in the absence of adaptive immunity","volume":"209","author":"Vermi","year":"2012","journal-title":"J. Exp. Med."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Tang, S., Ning, Q., Yang, L., Mo, Z., and Tang, S. (2020). Mechanisms of immune escape in the cancer immune cycle. Int. Immunopharmacol., 86.","DOI":"10.1016\/j.intimp.2020.106700"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"D769","DOI":"10.1093\/nar\/gkw946","article-title":"AAgAtlas 1.0: A human autoantigen database","volume":"45","author":"Wang","year":"2017","journal-title":"Nucleic Acids Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/nrc.2016.154","article-title":"Targeting neoantigens to augment antitumour immunity","volume":"17","author":"Yarchoan","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1002\/ijc.32889","article-title":"Beyond the concept of cold and hot tumors for the development of novel predictive biomarkers and the rational design of immunotherapy combination","volume":"147","author":"Dardenne","year":"2020","journal-title":"Int. J. Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Acebes-Fernandez, V., Landeira-Vinuela, A., Juanes-Velasco, P., Hernandez, A.-P., Otazo-Perez, A., Manzano-Roman, R., Gongora, R., and Fuentes, M. (2020). Nanomedicine and Onco-Immunotherapy: From the Bench to Bedside to Biomarkers. Nanomaterials, 10.","DOI":"10.3390\/nano10071274"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/nrc3380","article-title":"Immunogenic cell death and DAMPs in cancer therapy","volume":"12","author":"Krysko","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/s41418-017-0012-4","article-title":"Molecular mechanisms of cell death: Recommendations of the Nomenclature Committee on Cell Death 2018","volume":"25","author":"Galluzzi","year":"2018","journal-title":"Cell Death Differ."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/nri2545","article-title":"Immunogenic and tolerogenic cell death","volume":"9","author":"Green","year":"2009","journal-title":"Nat. Rev. Immunol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/nri.2016.107","article-title":"Immunogenic cell death in cancer and infectious disease","volume":"17","author":"Galluzzi","year":"2017","journal-title":"Nat. Rev. Immunol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.molcel.2014.03.003","article-title":"Mixed Lineage Kinase Domain-like Protein MLKL Causes Necrotic Membrane Disruption upon Phosphorylation by RIP3","volume":"54","author":"Wang","year":"2014","journal-title":"Mol. Cell"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1002\/1097-0215(200002)9999:9999<::AID-IJC1141>3.0.CO;2-X","article-title":"Induction and clonal expansion of tumor-specific cytotoxic T lymphocytes from renal cell carcinoma patients after stimulation with autologous dendritic cells loaded with tumor cells","volume":"91","author":"Kurokawa","year":"2001","journal-title":"Int. J. Cancer"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.cytogfr.2013.01.005","article-title":"Inducers of immunogenic cancer cell death","volume":"24","author":"Dudek","year":"2013","journal-title":"Cytokine Growth Factor Rev."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/nm1523","article-title":"Calreticulin exposure dictates the immunogenicity of cancer cell death","volume":"13","author":"Obeid","year":"2007","journal-title":"Nat. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.bbcan.2009.08.003","article-title":"Immunogenic cell death, DAMPs and anticancer therapeutics: An emerging amalgamation","volume":"1805","author":"Garg","year":"2010","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1096\/fj.09-145482","article-title":"Calreticulin: Non-endoplasmic reticulum functions in physiology and disease","volume":"24","author":"Gold","year":"2010","journal-title":"FASEB J."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1091\/mbc.e03-04-0251","article-title":"Impaired p53 expression, function, and nuclear localization in calreticulin-deficient cells","volume":"15","author":"Mesaeli","year":"2004","journal-title":"Mol. Biol. Cell"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/onc.2009.356","article-title":"Immunogenic death of colon cancer cells treated with oxaliplatin","volume":"29","author":"Tesniere","year":"2010","journal-title":"Oncogene"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/emboj.2009.1","article-title":"Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death","volume":"28","author":"Panaretakis","year":"2009","journal-title":"EMBO J."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1146\/annurev-immunol-032712-100008","article-title":"Immunogenic Cell Death in Cancer Therapy","volume":"31","author":"Kroemer","year":"2013","journal-title":"Annu. Rev. Immunol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1038\/nm.2028","article-title":"Activation of the NLRP3 inflammasome in dendritic cells induces IL-1 beta-dependent adaptive immunity against tumors","volume":"15","author":"Ghiringhelli","year":"2009","journal-title":"Nat. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1038\/s41418-017-0044-9","article-title":"eIF2 alpha phosphorylation is pathognomonic for immunogenic cell death","volume":"25","author":"Bezu","year":"2018","journal-title":"Cell Death Differ."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/cdd.2013.73","article-title":"Immunogenic calreticulin exposure occurs through a phylogenetically conserved stress pathway involving the chemokine CXCL8","volume":"21","author":"Sukkurwala","year":"2014","journal-title":"Cell Death Differ."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.jmb.2010.06.064","article-title":"A Mechanism of Release of Calreticulin from Cells During Apoptosis","volume":"401","author":"Tarr","year":"2010","journal-title":"J. Mol. Biol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"5931","DOI":"10.1038\/onc.2016.104","article-title":"Damage-associated molecular patterns in cancer: A double-edged sword","volume":"35","author":"Hernandez","year":"2016","journal-title":"Oncogene"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"3582","DOI":"10.4049\/jimmunol.177.6.3582","article-title":"Dendritic cell surface calreticulin is a receptor for NY-ESO-1: Direct interactions between tumor-associated antigen and the innate immune system","volume":"177","author":"Zeng","year":"2006","journal-title":"J. Immunol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1002\/cmdc.202000131","article-title":"Antitumour Anthracyclines: Progress and Perspectives","volume":"15","author":"Carvalho","year":"2020","journal-title":"Chemmedchem"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1007\/s13402-020-00544-2","article-title":"Mitoxantrone triggers immunogenic prostate cancer cell death via p53-dependent PERK expression","volume":"43","author":"Li","year":"2020","journal-title":"Cell. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1007\/s13402-020-00552-2","article-title":"Oxaliplatin induces immunogenic cell death in hepatocellular carcinoma cells and synergizes with immune checkpoint blockade therapy","volume":"43","author":"Zhu","year":"2020","journal-title":"Cell. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Walle, T., Martinez Monge, R., Cerwenka, A., Ajona, D., Melero, I., and Lecanda, F. (2018). Radiation effects on antitumor immune responses: Current perspectives and challenges. Ther. Adv. Med. Oncol., 10.","DOI":"10.1177\/1758834017742575"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1517\/14728222.2011.575360","article-title":"HMGB1, TLR and RAGE: A functional tripod that leads to diabetic inflammation","volume":"15","author":"Veloso","year":"2011","journal-title":"Expert Opin. Ther. Targets"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"224","DOI":"10.2119\/molmed.2011.00327","article-title":"High Mobility Group Box Protein 1 (HMGB1)-Partner Molecule Complexes Enhance Cytokine Production by Signaling Through the Partner Molecule Receptor","volume":"18","author":"Hreggvidsdottir","year":"2012","journal-title":"Mol. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1083\/jcb.200304135","article-title":"Extracellular HMGB1, a signal of tissue damage, induces mesoangioblast migration and proliferation","volume":"164","author":"Palumbo","year":"2004","journal-title":"J. Cell Biol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"7370","DOI":"10.1074\/jbc.M306793200","article-title":"Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein","volume":"279","author":"Park","year":"2004","journal-title":"J. Biol. Chem."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/imr.12601","article-title":"High-mobility group box 1 protein orchestrates responses to tissue damage via inflammation, innate and adaptive immunity, and tissue repair","volume":"280","author":"Bianchi","year":"2017","journal-title":"Immunol. Rev."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"11942","DOI":"10.1073\/pnas.1003893107","article-title":"A critical cysteine is required for HMGB1 binding to Toll-like receptor 4 and activation of macrophage cytokine release","volume":"107","author":"Yang","year":"2010","journal-title":"Proc. Natl. Acad. Sci. Am."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1089\/ars.2011.4367","article-title":"The Tumor Microenvironment: Characterization, Redox Considerations, and Novel Approaches for Reactive Oxygen Species-Targeted Gene Therapy","volume":"19","author":"Notcovich","year":"2013","journal-title":"Antioxid. Redox Signal."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1189\/jlb.1212662","article-title":"The many faces of HMGB1: Molecular structure-functional activity in inflammation, apoptosis, and chemotaxis","volume":"93","author":"Yang","year":"2013","journal-title":"J. Leukoc. Biol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1042\/bj2330309","article-title":"Extracellular ATP: Effects, sources and fate","volume":"233","author":"Gordon","year":"1986","journal-title":"Biochem. J."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/nature08296","article-title":"Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance","volume":"461","author":"Elliott","year":"2009","journal-title":"Nature"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/onc.2016.206","article-title":"Extracellular purines, purinergic receptors and tumor growth","volume":"36","author":"Adinolfi","year":"2017","journal-title":"Oncogene"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.4049\/jimmunol.166.3.1611","article-title":"Extracellular ATP induces a distorted maturation of dendritic cells and inhibits their capacity to initiate Th1 responses","volume":"166","author":"Ferrari","year":"2001","journal-title":"J. Immunol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.it.2012.02.009","article-title":"CD73: A potent suppressor of antitumor immune responses","volume":"33","author":"Beavis","year":"2012","journal-title":"Trends Immunol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1016\/j.freeradbiomed.2006.01.013","article-title":"PI3K-dependent lysosome exocytosis in nitric oxide-preconditioned hepatocytes","volume":"40","author":"Carini","year":"2006","journal-title":"Free Radic. Biol. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1038\/nature09413","article-title":"Pannexin 1 channels mediate \u2018find-me\u2019 signal release and membrane permeability during apoptosis","volume":"467","author":"Chekeni","year":"2010","journal-title":"Nature"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.4161\/auto.25873","article-title":"Autophagy-dependent ATP release from dying cells via lysosomal exocytosis","volume":"9","author":"Wang","year":"2013","journal-title":"Autophagy"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1111\/j.1582-4934.2008.00273.x","article-title":"Heat shock proteins: Essential proteins for apoptosis regulation","volume":"12","author":"Lanneau","year":"2008","journal-title":"J. Cell. Mol. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/nm0598-581","article-title":"Tumor immunogenicity is determined by the mechanism of cell death via induction of heat shock protein expression","volume":"4","author":"Melcher","year":"1998","journal-title":"Nat. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.4161\/cc.6.16.4601","article-title":"Towards a better way to die with chemotherapy\u2014Role of heat shock protein exposure on dying tumor cells","volume":"6","author":"Spisek","year":"2007","journal-title":"Cell Cycle"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Fucikova, J., Moserova, I., Urbanova, L., Bezu, L., Kepp, O., Cremer, I., Salek, C., Strnad, P., Kroemer, G., and Galluzzi, L. (2015). Prognostic and predictive value of DAMPs and DAMP-associated processes in cancer. Front. Immunol., 6.","DOI":"10.3389\/fimmu.2015.00402"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1126\/science.aad0779","article-title":"Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1","volume":"350","author":"Vacchelli","year":"2015","journal-title":"Science"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/nri3581","article-title":"Regulation of type I interferon responses","volume":"14","author":"Ivashkiv","year":"2014","journal-title":"Nat. Rev. Immunol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1038\/nm.3708","article-title":"Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy","volume":"20","author":"Sistigu","year":"2014","journal-title":"Nat. Med."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Aaes, T.L., and Vandenabeele, P. (2020). The intrinsic immunogenic properties of cancer cell lines, immunogenic cell death, and how these influence host antitumor immune responses. Cell Death Differ.","DOI":"10.1038\/s41418-020-00658-y"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1080\/2162402X.2017.1386829","article-title":"Trial watch: Immunogenic cell death induction by anticancer chemotherapeutics","volume":"6","author":"Garg","year":"2017","journal-title":"Oncoimmunology"},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Talib, W.H., Alsalahat, I., Daoud, S., Abutayeh, R.F., and Mahmod, A.I. (2020). Plant-Derived Natural Products in Cancer Research: Extraction, Mechanism of Action, and Drug Formulation. Molecules, 25.","DOI":"10.3390\/molecules25225319"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1124\/pr.56.2.6","article-title":"Anthracyclines: Molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity","volume":"56","author":"Minotti","year":"2004","journal-title":"Pharmacol. Rev."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1084\/jem.20050915","article-title":"Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death","volume":"202","author":"Casares","year":"2005","journal-title":"J. Exp. Med."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"4821","DOI":"10.1158\/0008-5472.CAN-11-0950","article-title":"Human Tumor Cells Killed by Anthracyclines Induce a Tumor-Specific Immune Response","volume":"71","author":"Fucikova","year":"2011","journal-title":"Cancer Res."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1158\/0008-5472.CAN-09-3566","article-title":"Tumor Cell Death and ATP Release Prime Dendritic Cells and Efficient Anticancer Immunity","volume":"70","author":"Aymeric","year":"2010","journal-title":"Cancer Res."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.immuni.2013.03.003","article-title":"Anticancer Chemotherapy-Induced Intratumoral Recruitment and Differentiation of Antigen-Presenting Cells","volume":"38","author":"Ma","year":"2013","journal-title":"Immunity"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1084\/jem.20100269","article-title":"Contribution of IL-17-producing gamma delta T cells to the efficacy of anticancer chemotherapy","volume":"208","author":"Ma","year":"2011","journal-title":"J. Exp. Med."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"703","DOI":"10.3892\/etm.2014.1489","article-title":"Doxorubicin treatment induces tumor cell death followed by immunomodulation in a murine neuroblastoma model","volume":"7","author":"Inoue","year":"2014","journal-title":"Exp. Ther. Med."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Castoldi, F., Vacchelli, E., Zitvogel, L., Maiuri, M.C., Pietrocola, F., and Kroemer, G. (2019). Systemic autophagy in the therapeutic response to anthracycline-based chemotherapy. Oncoimmunology, 8.","DOI":"10.1080\/2162402X.2018.1498285"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1080\/2162402X.2019.1703449","article-title":"Trial watch: Chemotherapy-induced immunogenic cell death in immuno-oncology","volume":"9","author":"Vanmeerbeek","year":"2020","journal-title":"Oncoimmunology"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/ptr.1100","article-title":"Cellular pharmacology studies of shikonin derivatives","volume":"16","author":"Chen","year":"2002","journal-title":"Phytother. Res."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1248\/bpb.33.816","article-title":"Shikonin Induces Apoptosis through Reactive Oxygen Species\/Extracellular Signal-Regulated Kinase Pathway in Osteosarcoma Cells","volume":"33","author":"Chang","year":"2010","journal-title":"Biol. Pharm. Bull."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1007\/s00262-012-1258-9","article-title":"Shikonin induces immunogenic cell death in tumor cells and enhances dendritic cell-based cancer vaccine","volume":"61","author":"Chen","year":"2012","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1080\/15548627.2017.1386359","article-title":"Necroptosis promotes autophagy-dependent upregulation of DAMP and results in immunosurveillance","volume":"14","author":"Lin","year":"2018","journal-title":"Autophagy"},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Lin, T.J., Lin, H.T., Chang, W.T., Mitapalli, S.P., Hsiao, P.W., Yin, S.Y., and Yang, N.S. (2015). Shikonin-enhanced cell immunogenicity of tumor vaccine is mediated by the differential effects of DAMP components. Mol. Cancer, 14.","DOI":"10.1186\/s12943-015-0435-9"},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Chen, Y., Gao, Y., Yi, X., Zhang, J., Chen, Z., and Wu, Y. (2020). Integration of Transcriptomics and Metabolomics Reveals the Antitumor Mechanism Underlying Shikonin in Colon Cancer. Front. Pharmacol., 11.","DOI":"10.3389\/fphar.2020.544647"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S0140-6736(79)90996-6","article-title":"CARDIAC-GLYCOSIDES AND BREAST-CANCER","volume":"1","author":"Stenkvist","year":"1979","journal-title":"Lancet"},{"key":"ref_78","first-page":"109","article-title":"Cardiac glycosides in cancer research and cancer therapy","volume":"63","author":"Winnicka","year":"2006","journal-title":"Acta Pol. Pharm."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1038\/nrd2682","article-title":"Novel therapeutic applications of cardiac glycosides","volume":"7","author":"Prassas","year":"2008","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Menger, L., Vacchelli, E., Adjemian, S., Martins, I., Ma, Y.T., Shen, S.S., Yamazaki, T., Sukkurwala, A.Q., Michaud, M., and Mignot, G. (2012). Cardiac Glycosides Exert Anticancer Effects by Inducing Immunogenic Cell Death. Sci. Transl. Med., 4.","DOI":"10.1126\/scitranslmed.3003807"},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Menger, L., Vacchelli, E., Kepp, O., Eggermont, A., Tartour, E., Zitvogel, L., Kroemer, G., and Galluzzi, L. (2013). Trial watch Cardiac glycosides and cancer therapy. Oncoimmunology, 2.","DOI":"10.4161\/onci.23082"},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Sukkurwala, A.Q., Adjemian, S., Senovilla, L., Michaud, M., Spaggiari, S., Vacchelli, E., Baracco, E.E., Galluzzi, L., Zitvogel, L., and Kepp, O. (2014). Screening of novel immunogenic cell death inducers within the NCI Mechanistic Diversity Set. Oncoimmunology, 3.","DOI":"10.4161\/onci.28473"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.3892\/or.2016.4946","article-title":"Effects of active bufadienolide compounds on human cancer cells and CD4(+)CD25(+)Foxp3(+) regulatory T cells in mitogen-activated human peripheral blood mononuclear cells","volume":"36","author":"Yuan","year":"2016","journal-title":"Oncol. Rep."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Pol, J., Vacchelli, E., Aranda, F., Castoldi, F., Eggermont, A., Cremer, I., Sautes-Fridman, C., Fucikova, J., Galon, J., and Spisek, R. (2015). Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy. Oncoimmunology, 4.","DOI":"10.1080\/2162402X.2015.1008866"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1126\/science.1224922","article-title":"An Immunosurveillance Mechanism Controls Cancer Cell Ploidy","volume":"337","author":"Senovilla","year":"2012","journal-title":"Science"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1038\/gt.2010.121","article-title":"Synergistic anti-tumor effects between oncolytic vaccinia virus and paclitaxel are mediated by the IFN response and HMGB1","volume":"18","author":"Huang","year":"2011","journal-title":"Gene Ther."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.cellimm.2010.03.001","article-title":"Paclitaxel enhances early dendritic cell maturation and function through TLR4 signaling in mice","volume":"263","author":"Pfannenstiel","year":"2010","journal-title":"Cell. Immunol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1158\/2326-6066.CIR-19-0616","article-title":"Paclitaxel Induces Immunogenic Cell Death in Ovarian Cancer via TLR4\/IKK2\/SNARE-Dependent Exocytosis","volume":"8","author":"Lau","year":"2020","journal-title":"Cancer Immunol. Res."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1158\/1535-7163.MCT-14-0636","article-title":"Tumor-Related Molecular Mechanisms of Oxaliplatin Resistance","volume":"14","author":"Gines","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"3723","DOI":"10.4161\/cc.8.22.10026","article-title":"Chemotherapy induces ATP release from tumor cells","volume":"8","author":"Martins","year":"2009","journal-title":"Cell Cycle"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1038\/nm1622","article-title":"Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy","volume":"13","author":"Apetoh","year":"2007","journal-title":"Nat. Med."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"18538","DOI":"10.1073\/pnas.0509182102","article-title":"Intraepithelial CD8(+) tumor-infiltrating lymphocytes and a high CD8(+)\/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer","volume":"102","author":"Sato","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_93","first-page":"2335","article-title":"Intraperitoneal oxaliplatin administration inhibits the tumor immunosuppressive microenvironment in an abdominal implantation model of colon cancer","volume":"18","author":"Gou","year":"2018","journal-title":"Mol. Med. Rep."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s11060-018-2979-1","article-title":"Oxaliplatin disrupts pathological features of glioma cells and associated macrophages independent of apoptosis induction","volume":"140","author":"Roberts","year":"2018","journal-title":"J. Neuro-Oncol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.oraloncology.2019.06.016","article-title":"Cisplatin and oxaliplatin induce similar immunogenic changes in preclinical models of head and neck cancer","volume":"95","author":"Park","year":"2019","journal-title":"Oral Oncol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/nrclinonc.2010.82","article-title":"Metronomic chemotherapy: New rationale for new directions","volume":"7","author":"Pasquier","year":"2010","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bbrc.2016.12.180","article-title":"Chemoimmunotherapy by combining oxaliplatin with immune checkpoint blockades reduced tumor burden in colorectal cancer animal model","volume":"487","author":"Wang","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1080\/10799893.2019.1655050","article-title":"Oxaliplatin induces immunogenic cells death and enhances therapeutic efficacy of checkpoint inhibitor in a model of murine lung carcinoma","volume":"39","author":"Sun","year":"2019","journal-title":"J. Recept. Signal Transduct."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"555","DOI":"10.2174\/1381612805666230110214512","article-title":"An overview of cyclophosphamide development and clinical applications","volume":"5","author":"Colvin","year":"1999","journal-title":"Curr. Pharm. Des."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1158\/0008-5472.CAN-10-2788","article-title":"Cyclophosphamide Synergizes with Type I Interferons through Systemic Dendritic Cell Reactivation and Induction of Immunogenic Tumor Apoptosis","volume":"71","author":"Schiavoni","year":"2011","journal-title":"Cancer Res."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1182\/blood.V95.6.2024","article-title":"Cyclophosphamide induces type I interferon and augments the number of CD44(hi) T lymphocytes in mice: Implications for strategies of chemoimmunotherapy of cancer","volume":"95","author":"Schiavoni","year":"2000","journal-title":"Blood"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/S0959-8049(00)00044-7","article-title":"Mechanism of antimetastatic immunopotentiation by low-dose cyclophosphamide","volume":"36","author":"Matar","year":"2000","journal-title":"Eur. J. Cancer"},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Doloff, J.C., and Waxman, D.J. (2015). Transcriptional profiling provides insights into metronomic cyclophosphamide-activated, innate immune-dependent regression of brain tumor xenografts. BMC Cancer, 15.","DOI":"10.1186\/s12885-015-1358-y"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s00262-006-0225-8","article-title":"Metronomic cyclophosphamide regimen selectively depletes CD4(+) CD25(+) regulatory T cells and restores T and NK effector functions in end stage cancer patients","volume":"56","author":"Ghiringhelli","year":"2007","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/j.1365-2249.2007.03521.x","article-title":"Increase of CD4(+)CD25(+) regulatory T cells in the peripheral blood of patients with metastatic carcinoma: A Phase I clinical trial using cyclophosphamide and immunotherapy to eliminate CD4(+)CD25(+) T lymphocytes","volume":"150","author":"Audia","year":"2007","journal-title":"Clin. Exp. Immunol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"239","DOI":"10.2174\/156800911794519752","article-title":"Bortezomib as the First Proteasome Inhibitor Anticancer Drug: Current Status and Future Perspectives","volume":"11","author":"Chen","year":"2011","journal-title":"Curr. Cancer Drug Targets"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"11510","DOI":"10.1158\/0008-5472.CAN-05-2394","article-title":"Bortezomib inhibits PKR-like endoplasmic reticulum (ER) kinase and induces apoptosis via ER stress in human pancreatic cancer cells","volume":"65","author":"Nawrocki","year":"2005","journal-title":"Cancer Res."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"4839","DOI":"10.1182\/blood-2006-10-054221","article-title":"Bortezomib enhances dendritic cell (DC)-mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: Therapeutic implications","volume":"109","author":"Spisek","year":"2007","journal-title":"Blood"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.4049\/jimmunol.1103826","article-title":"Immune Mechanism of the Antitumor Effects Generated by Bortezomib","volume":"189","author":"Chang","year":"2012","journal-title":"J. Immunol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"8604","DOI":"10.18632\/oncotarget.14365","article-title":"Bortezomib augments lymphocyte stimulatory cytokine signaling in the tumor microenvironment to sustain CD8(+)T cell antitumor function","volume":"8","author":"Pellom","year":"2017","journal-title":"Oncotarget"},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Hontecillas-Prieto, L., Flores-Campos, R., Silver, A., de Alava, E., Hajji, N., and Garcia-Dominguez, D.J. (2020). Synergistic Enhancement of Cancer Therapy Using HDAC Inhibitors: Opportunity for Clinical Trials. Front. Genet., 11.","DOI":"10.3389\/fgene.2020.578011"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1182\/blood-2006-06-025999","article-title":"Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma, (CTCL)","volume":"109","author":"Duvic","year":"2007","journal-title":"Blood"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.it.2011.04.001","article-title":"Histone deacetylases as regulators of inflammation and immunity","volume":"32","author":"Shakespear","year":"2011","journal-title":"Trends Immunol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1007\/s00280-010-1302-4","article-title":"The histone deacetylase inhibitor vorinostat induces calreticulin exposure in childhood brain tumour cells in vitro","volume":"66","author":"Sonnemann","year":"2010","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"7265","DOI":"10.1158\/0008-5472.CAN-13-0890","article-title":"An Intact Immune System Is Required for the Anticancer Activities of Histone Deacetylase Inhibitors","volume":"73","author":"West","year":"2013","journal-title":"Cancer Res."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"6623","DOI":"10.1158\/1078-0432.CCR-19-1305","article-title":"Phase I\/Ib Study of Pembrolizumab Plus Vorinostat in Advanced\/Metastatic Non-Small Cell Lung Cancer","volume":"25","author":"Gray","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/j.drudis.2012.04.006","article-title":"The future of antibodies as cancer drugs","volume":"17","author":"Reichert","year":"2012","journal-title":"Drug Discov. Today"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1089\/1536859041224280","article-title":"7A7 MAb: A new tool for the pre-clinical evaluation of EGFR-based therapies","volume":"23","author":"Garrido","year":"2004","journal-title":"Hybrid. Hybridomics"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"4954","DOI":"10.4049\/jimmunol.1003477","article-title":"Induction of Immunogenic Apoptosis by Blockade of Epidermal Growth Factor Receptor Activation with a Specific Antibody","volume":"187","author":"Garrido","year":"2011","journal-title":"J. Immunol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1038\/onc.2013.288","article-title":"Preclinical modeling of EGFR-specific antibody resistance: Oncogenic and immune-associated escape mechanisms","volume":"33","author":"Garrido","year":"2014","journal-title":"Oncogene"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"12250","DOI":"10.18632\/oncotarget.24242","article-title":"Characterization of 7A7, an anti-mouse EGFR monoclonal antibody proposed to be the mouse equivalent of cetuximab","volume":"9","author":"He","year":"2018","journal-title":"Oncotarget"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/nm.4078","article-title":"The EGFR-specific antibody cetuximab combined with chemotherapy triggers immunogenic cell death","volume":"22","author":"Pozzi","year":"2016","journal-title":"Nat. Med."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/cas.13162","article-title":"Cetuximab strongly enhances immune cell infiltration into liver metastatic sites in colorectal cancer","volume":"108","author":"Inoue","year":"2017","journal-title":"Cancer Sci."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1517\/14712598.1.3.525","article-title":"Oncolytic virotherapy for cancer with the adenovirus dl1520 (Onyx-015): Results of Phase I and II trials","volume":"1","author":"Kirn","year":"2001","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1586\/14737140.8.10.1581","article-title":"Oncolytic viruses: A novel form of immunotherapy","volume":"8","author":"Prestwich","year":"2008","journal-title":"Expert Rev. Anticancer Ther."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/cgt.2016.8","article-title":"Immunogenic cell death by oncolytic herpes simplex virus type 1 in squamous cell carcinoma cells","volume":"23","author":"Takasu","year":"2016","journal-title":"Cancer Gene Ther."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.2147\/OTT.S126320","article-title":"Immunogenicity of oncolytic vaccinia viruses JX-GFP and TG6002 in a human melanoma in vitro model: Studying immunogenic cell death, dendritic cell maturation and interaction with cytotoxic T lymphocytes","volume":"10","author":"Heinrich","year":"2017","journal-title":"Oncotargets Ther."},{"key":"ref_128","first-page":"1514","article-title":"Oncolytic Newcastle disease virus induces autophagy-dependent immunogenic cell death in lung cancer cells","volume":"8","author":"Ye","year":"2018","journal-title":"Am. J. Cancer Res."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s12943-020-01275-6","article-title":"Improving antitumor efficacy via combinatorial regimens of oncolytic virotherapy","volume":"19","author":"Zhang","year":"2020","journal-title":"Mol. Cancer"},{"key":"ref_130","unstructured":"Institute, N.C. (2020, January 10). Radiation Therapy to Treat Cancer, Available online: https:\/\/www.cancer.gov\/about-cancer\/treatment\/types\/radiation-therapy."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/S1470-2045(09)70082-8","article-title":"Systemic effects of local radiotherapy","volume":"10","author":"Formenti","year":"2009","journal-title":"Lancet Oncol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"321","DOI":"10.2307\/3578216","article-title":"Induction of the expression of the interleukin-1 beta gene in mouse spleen by ionizing radiation","volume":"133","author":"Ishihara","year":"1993","journal-title":"Radiat. Res."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1084\/jem.20052494","article-title":"Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy","volume":"203","author":"Reits","year":"2006","journal-title":"J. Exp. Med."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1667\/RR1860.1","article-title":"Up-regulation of the Pro-inflammatory Chemokine CXCL16 is a Common Response of Tumor Cells to Ionizing Radiation","volume":"173","author":"Matsumura","year":"2010","journal-title":"Radiat. Res."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"403","DOI":"10.18632\/oncotarget.1719","article-title":"Radiation-induced immunogenic modulation of tumor enhances antigen processing and calreticulin exposure, resulting in enhanced T-cell killing","volume":"5","author":"Gameiro","year":"2014","journal-title":"Oncotarget"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"6859","DOI":"10.2147\/OTT.S253772","article-title":"HMGB1 in Radiotherapy: A Two Headed Signal Regulating Tumor Radiosensitivity and Immunity","volume":"13","author":"Liao","year":"2020","journal-title":"Oncotargets Ther."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/imr.12572","article-title":"Immunomodulation by ionizing radiation-impact for design of radio-immunotherapies and for treatment of inflammatory diseases","volume":"280","author":"Frey","year":"2017","journal-title":"Immunol. Rev."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/nrc1071","article-title":"Photodynamic therapy for cancer","volume":"3","author":"Dolmans","year":"2003","journal-title":"Nat. Rev. Cancer"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.pdpdt.2012.01.008","article-title":"A basic study on Hypericin-PDT in vitro","volume":"9","author":"Nakajima","year":"2012","journal-title":"Photodiagnosis Photodyn. Ther."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1007\/s00018-007-7030-1","article-title":"Hypericin photoactivation triggers down-regulation of matrix metalloproteinase-9 expression in well-differentiated human nasopharyngeal cancer cells","volume":"64","author":"Du","year":"2007","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.bbcan.2019.07.003","article-title":"Cell death in photodynamic therapy: From oxidative stress to anti-tumor immunity","volume":"1872","author":"Donohoe","year":"2019","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"ref_142","doi-asserted-by":"crossref","unstructured":"Cheng, Y., Cheng, H., Jiang, C., Qiu, X., Wang, K., Huan, W., Yuan, A., Wu, J., and Hu, Y. (2015). Perfluorocarbon nanoparticles enhance reactive oxygen levels and tumour growth inhibition in photodynamic therapy. Nat. Commun., 6.","DOI":"10.1038\/ncomms9785"},{"key":"ref_143","doi-asserted-by":"crossref","unstructured":"Li, W., Yang, J., Luo, L., Jiang, M., Qin, B., Yin, H., Zhu, C., Yuan, X., Zhang, J., and Luo, Z. (2019). Targeting photodynamic and photothermal therapy to the endoplasmic reticulum enhances immunogenic cancer cell death. Nat. Commun., 10.","DOI":"10.1038\/s41467-019-11269-8"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1021\/acsnano.9b07212","article-title":"Smart Nanovesicle-Mediated Immunogenic Cell Death through Tumor Microenvironment Modulation for Effective Photodynamic Immunotherapy","volume":"14","author":"Yang","year":"2020","journal-title":"ACS Nano"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3389\/fonc.2019.00811","article-title":"Low Photosensitizer Dose and Early Radiotherapy Enhance Antitumor Immune Response of Photodynamic Therapy-Based Dendritic Cell Vaccination","volume":"9","author":"Doix","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"4297","DOI":"10.1038\/onc.2011.137","article-title":"Shikonin and its analogs inhibit cancer cell glycolysis by targeting tumor pyruvate kinase-M2","volume":"30","author":"Chen","year":"2011","journal-title":"Oncogene"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"6051","DOI":"10.1038\/onc.2010.335","article-title":"Low-dose paclitaxel synergizes with oncolytic adenoviruses via mitotic slippage and apoptosis in ovarian cancer","volume":"29","author":"Ingemarsdotter","year":"2010","journal-title":"Oncogene"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.omto.2018.02.001","article-title":"Oncolytic Immunotherapy for Bladder Cancer Using Coxsackie A21 Virus","volume":"9","author":"Annels","year":"2018","journal-title":"Mol. Ther. Oncolytics"},{"key":"ref_149","first-page":"1","article-title":"Quantitation of calreticulin exposure associated with immunogenic cell death","volume":"632","author":"Liu","year":"2020","journal-title":"Tumor Immunol. Immunother. Cell. Methods Pt B"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"10","DOI":"10.21037\/atm.2019.09.128","article-title":"Comparison of the effects of photon, proton and carbon-ion radiation on the ecto-calreticulin exposure in various tumor cell lines","volume":"7","author":"Huang","year":"2019","journal-title":"Ann. Transl. Med."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.3324\/haematol.2019.223933","article-title":"Calreticulin exposure on malignant blasts correlates with improved natural killer cell-mediated cytotoxicity in acute myeloid leukemia patients","volume":"105","author":"Truxova","year":"2020","journal-title":"Haematologica"},{"key":"ref_152","doi-asserted-by":"crossref","unstructured":"Kasikova, L., Hensler, M., Truxova, I., Skapa, P., Laco, J., Belicova, L., Praznovec, I., Vosahlikova, S., Halaska, M.J., and Brtnicky, T. (2019). Calreticulin exposure correlates with robust adaptive antitumor immunity and favorable prognosis in ovarian carcinoma patients. J. Immunother. Cancer, 7.","DOI":"10.1186\/s40425-019-0781-z"},{"key":"ref_153","doi-asserted-by":"crossref","unstructured":"Han, A., Li, C., Zahed, T., Wong, M., Smith, I., Hoedel, K., Green, D., and Boiko, A.D. (2019). Calreticulin is a Critical Cell Survival Factor in Malignant Neoplasms. PloS Biol., 17.","DOI":"10.1371\/journal.pbio.3000402"},{"key":"ref_154","doi-asserted-by":"crossref","unstructured":"Tatsuno, K., Yamazaki, T., Hanlon, D., Han, P., Robinson, E., Sobolev, O., Yurter, A., Rivera-Molina, F., Arshad, N., and Edelson, R.L. (2019). Extracorporeal photochemotherapy induces bona fide immunogenic cell death. Cell Death Dis., 10.","DOI":"10.1038\/s41419-019-1819-3"},{"key":"ref_155","doi-asserted-by":"crossref","unstructured":"Hongo, K., Kazama, S., Tsuno, N.H., Ishihara, S., Sunami, E., Kitayama, J., and Watanabe, T. (2015). Immunohistochemical detection of high-mobility group box 1 correlates with resistance of preoperative chemoradiotherapy for lower rectal cancer: A retrospective study. World J. Surg. Oncol., 13.","DOI":"10.1186\/1477-7819-13-7"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1089\/ars.2015.6406","article-title":"Redox-Dependent HMGB1 Isoforms as Pivotal Co-Ordinators of Drug-Induced Liver Injury: Mechanistic Biomarkers and Therapeutic Targets","volume":"24","author":"Lea","year":"2016","journal-title":"Antioxid. Redox Signal."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/bs.mie.2019.10.006","article-title":"Luciferase-assisted detection of extracellular ATP and ATP metabolites during immunogenic death of cancer cells","volume":"629","author":"Dubyak","year":"2019","journal-title":"Tumor Immunol. Immunother. Mol. Methods"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/978-1-4939-9717-6_15","article-title":"Fluorescent Labeling and Quantification of Vesicular ATP Release Using Live Cell Imaging","volume":"2041","author":"Vessey","year":"2020","journal-title":"Purinergic Signal. Methods Protoc."},{"key":"ref_159","doi-asserted-by":"crossref","unstructured":"Giglio, P., Gagliardi, M., Tumino, N., Antunes, F., Smaili, S., Cotella, D., Santoro, C., Bernardini, R., Mattei, M., and Piacentini, M. (2018). PKR and GCN2 stress kinases promote an ER stress-independent eIF2 alpha phosphorylation responsible for calreticulin exposure in melanoma cells. Oncoimmunology, 7.","DOI":"10.1080\/2162402X.2018.1466765"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1080\/2162402X.2020.1747350","article-title":"Doxorubicin pretreatment enhances FAP alpha\/survivin co-targeting DNA vaccine anti-tumor activity primarily through decreasing peripheral MDSCs in the 4T1 murine breast cancer model","volume":"9","author":"Geng","year":"2020","journal-title":"Oncoimmunology"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/nrc3258","article-title":"Cancer immunotherapy via dendritic cells","volume":"12","author":"Palucka","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.7150\/thno.24699","article-title":"DNA damage predicts prognosis and treatment response in colorectal liver metastases superior to immunogenic cell death and T cells","volume":"8","author":"Laengle","year":"2018","journal-title":"Theranostics"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1158\/0008-5472.CAN-15-1142","article-title":"Calreticulin Expression in Human Non-Small Cell Lung Cancers Correlates with Increased Accumulation of Antitumor Immune Cells and Favorable Prognosis","volume":"76","author":"Fucikova","year":"2016","journal-title":"Cancer Res."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1002\/ijc.27894","article-title":"Immunogenic cell death biomarkers HMGB1, RAGE, and DNAse indicate response to radioembolization therapy and prognosis in colorectal cancer patients","volume":"132","author":"Fahmueller","year":"2013","journal-title":"Int. J. Cancer"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"11091","DOI":"10.1073\/pnas.1222251110","article-title":"CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer","volume":"110","author":"Loi","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_166","doi-asserted-by":"crossref","unstructured":"Ladoire, S., Enot, D., Andre, F., Zitvogel, L., and Kroemer, G. (2016). Immunogenic cell death-related biomarkers: Impact on the survival of breast cancer patients after adjuvant chemotherapy. Oncoimmunology, 5.","DOI":"10.1080\/2162402X.2015.1082706"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s13277-012-0513-1","article-title":"Circulating immunogenic cell death biomarkers HMGB1 and RAGE in breast cancer patients during neoadjuvant chemotherapy","volume":"34","author":"Stoetzer","year":"2013","journal-title":"Tumor Biol."},{"key":"ref_168","doi-asserted-by":"crossref","unstructured":"Rapoport, B.L., and Anderson, R. (2019). Realizing the Clinical Potential of Immunogenic Cell Death in Cancer Chemotherapy and Radiotherapy. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20040959"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1039\/C7MT00068E","article-title":"Decoding the anticancer activity of VO-clioquinol compound: The mechanism of action and cell death pathways in human osteosarcoma cells","volume":"9","author":"Leon","year":"2017","journal-title":"Metallomics"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1039\/C6MT00045B","article-title":"Deciphering the effect of an oxovanadium(IV) complex with the flavonoid chrysin (VOChrys) on intracellular cell signalling pathways in an osteosarcoma cell line","volume":"8","author":"Leon","year":"2016","journal-title":"Metallomics"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1007\/s12272-019-01150-z","article-title":"Natural compound inducers of immunogenic cell death","volume":"42","author":"Diederich","year":"2019","journal-title":"Arch. Pharmacal Res."},{"key":"ref_172","doi-asserted-by":"crossref","unstructured":"Juanes-Velasco, P., Carabias-Sanchez, J., Garcia-Valiente, R., Fernandez-Garc\u00eda, J., Gongora, R., Gonzalez-Gonzalez, M., and Fuentes, M. (2018). Microarrays as Platform for Multiplex Assays in Biomarker and Drug Discovery. Rapid Test-Advances in Design, Format and Diagnostic Applications, IntechOpen.","DOI":"10.5772\/intechopen.75614"},{"key":"ref_173","doi-asserted-by":"crossref","unstructured":"Kepp, O., Senovilla, L., Vitale, I., Vacchelli, E., Adjemian, S., Agostinis, P., Apetoh, L., Aranda, F., Barnaba, V., and Bloy, N. (2014). Consensus guidelines for the detection of immunogenic cell death. Oncoimmunology, 3.","DOI":"10.4161\/21624011.2014.955691"},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1074\/mcp.R119.001743","article-title":"The Human Immunopeptidome Project: A Roadmap to Predict and Treat Immune Diseases","volume":"19","author":"Vizcaino","year":"2020","journal-title":"Mol. Cell. Proteom."},{"key":"ref_175","first-page":"424","article-title":"Deciphering Human Leukocyte Antigen susceptibility maps from immunopeptidomics characterization in oncology and infections","volume":"11","author":"Montalvillo","year":"2021","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1002\/cam4.827","article-title":"Prognostic value of HMGB1 in early breast cancer patients under neoadjuvant chemotherapy","volume":"5","author":"Exner","year":"2016","journal-title":"Cancer Med."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/11\/2821\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:11:15Z","timestamp":1760163075000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/11\/2821"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,5]]},"references-count":176,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2021,6]]}},"alternative-id":["cancers13112821"],"URL":"https:\/\/doi.org\/10.3390\/cancers13112821","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,5]]}}}